Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 0

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 0
---
TABLE OF CONTENTS

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-289589 PROSPECTUS SUPPLEMENT
(To Prospectus dated August 20, 2025) 18,959,914 Shares of Class A Common Stock We are offering 18,959,914 shares of our Class A common stock, at a price of $9.23 per share. Our Class A common stock is listed on The Nasdaq Global Market under the symbol “IMRX.” On September 23, 2025, the last reported sale price for our Class A common stock on The Nasdaq Global Market was $8.59 per share. On September 24, 2025, we entered into a securities purchase agreement with Aventis Inc. (referred to herein as the Investor), a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Investor agreed to purchase, subject to certain conditions, up to $25.0 million of our Class A common stock, or in certain situations in lieu of shares of Class A common stock, shares of our non-voting Class B common stock, in a private placement. Under the terms of the securities purchase agreement, the private placement is subject to and contingent upon the closing of a firm commitment underwritten public offering by us of our Class A common stock that results in gross proceeds to us of at least $75.0 million and the pricing of which is publicly announced in a press release issued by us on or before September 26, 2025 (referred to herein as a qualified public offering), and is expected to close concurrent with the completion of the qualified public offering. The purchase price per share of Class A common stock (or per share of Class B common stock in lieu of Class A common stock) shall be the public offering price per share at which our Class A common stock is sold to the public in the qualified public offering. The sale of the shares in the concurrent private placement will not be registered under the Securities Act of 1933, as amended, or the Act. The closing of this offering is not conditioned upon the closing of the concurrent private placement. Under the terms of the securities purchase agreement, this offering constitutes a qualified public offering. Accordingly, pursuant to the securities purchase agreement, subject to the closing of this offering and the other conditions set forth therein, the Investor has agreed to purchase, and we have agreed to issue and sell to the Investor, an aggregate of 2,708,559